ProQR Therapeutics (NASDAQ:PRQR) Receives $9.50 Consensus PT from Analysts
Shares of ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) have been assigned an average recommendation of “Buy” from the six brokerages that are presently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price […]
Shares of ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) have been assigned an average recommendation of “Buy” from the six brokerages that are presently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price […]
